Drug intelligence / Profile preview

MK-3281

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-3281 is a potent, orally bioavailable small molecule inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. It is a non-nucleoside inhibitor that binds to an allosteric site on the thumb domain of the NS5B polymerase, interfering with viral replication. Preclinical studies demonstrated efficacy in cell-based assays against HCV genotypes 1 and 3, as well as in vivo activity in chimeric mouse and chimpanzee models of HCV infection. The drug was developed for chronic HCV infection and reached Phase I clinical trials, where it showed good pharmacokinetic properties and was generally well tolerated[2][4][5][7].

Other names: UNII-3593C180JOUNII3593C180JOUNII 3593C180JO886041-60-7

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on MK-3281.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-3281.

Explore the full profile